Skip to main content

Boston Scientific Value Stock - Dividend - Research Selection

Boston scientific

ISIN: US1011371077 , WKN: 884113

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson\'s disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


BTIG Maintains Boston Scientific (BSX) Buy Recommendation

2025-10-01

Needham Reiterates Boston Scientific (BSX) Buy Recommendation

2025-10-01

Defensive stocks show deep value as cyclicals run hot, UBS says

2025-09-30
Investing.com-- Defensive plays like healthcare equipment and benchmark pharma now offer deeper value at a time when cyclical sectors are trading at historically expensive levels and are pricing in a sharp earnings reboundd despite cooling domestic demand in the US and stuttering Eurozone growth.

Piper Sandler Reaffirms its Overweight Rating and $115 Price Target on Boston Scientific Corporation (BSX)

2025-09-30
Boston Scientific Corporation (NYSE:BSX) is one of the 14 Stocks That Will Double in the Next 5 Years. On September 25, 2025, Piper Sandler reaffirmed its Overweight rating and $115 price target on Boston Scientific Corporation (NYSE:BSX), a $145.3 billion medical products company, citing confidence in the CHAMPION-AF study as a major growth driver for its Watchman […]

2025 Investor Day Call

2025-09-30
2025-09-30. The following slide deck was published by Boston Scientific Corporation in conjunction with this event.

Boston Scientific Corporation (BSX) Analyst/Investor Day Transcript

2025-09-30
Discover Boston Scientific's latest investor insights, 3-year growth strategies

RBC Capital Reiterates Boston Scientific (BSX) Outperform Recommendation

2025-09-30

Boston Scientific Corp. stock underperforms Monday when compared to competitors

2025-09-29
Boston Scientific Corp. stock underperforms Monday when compared to competitors

IDEXX Laboratories Stock Rallies 52.9% YTD: What's Behind the Drive?

2025-09-29
IDXX soars 52.9% YTD, fueled by strong CAG Diagnostics growth, global expansion and rising demand for software solutions.

Insulet Stock Surges 37.4% in 12 months: What's Driving the Rally?

2025-09-26
PODD stock rallies 37.4% in a year, fueled by Omnipod 5 adoption, global launches and expanding reach in diabetes care.